Blume Capital Management’s Corcept Therapeutics CORT Stock Holding History

Blume Capital Management’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-700	Closed	-$14K	–	302
2021 Q3	$14K	Hold	700	–	–	0.01%	241
2021 Q2	$15K	Hold	700	–	–	0.01%	224
2021 Q1	$17K	Hold	700	–	–	0.01%	205
2020 Q4	$18K	Hold	700	–	–	0.01%	169
2020 Q3	$12K	Hold	700	–	–	0.01%	171
2020 Q2	$12K	Hold	700	–	–	0.01%	166
2020 Q1	$8K	Hold	700	–	–	0.01%	181
2019 Q4	$8K	Hold	700	–	–	﹤0.01%	190
2019 Q3	$9K	Hold	700	–	–	﹤0.01%	186
2019 Q2	$8K	Hold	700	–	–	﹤0.01%	184
2019 Q1	$8K	Hold	700	–	–	﹤0.01%	196
2018 Q4	$9K	Hold	700	–	–	0.01%	186
2018 Q3	$10K	Hold	700	–	–	0.01%	162
2018 Q2	$11K	Hold	700	–	–	0.01%	159
2018 Q1	$11K	Hold	700	–	–	0.01%	171
2017 Q4	$13K	Hold	700	–	–	0.01%	181
2017 Q3	$14K	Hold	700	–	–	0.01%	183
2017 Q2	$8K	Hold	700	–	–	﹤0.01%	166
2017 Q1	$8K	Hold	700	–	–	﹤0.01%	158
2016 Q4	$5K	Hold	700	–	–	﹤0.01%	182
2016 Q3	$5K	Hold	700	–	–	﹤0.01%	173
2016 Q2	$4K	Hold	700	–	–	﹤0.01%	196
2016 Q1	$3K	Hold	700	–	–	﹤0.01%	223
2015 Q4	$3K	Hold	700	–	–	﹤0.01%	220
2015 Q3	$3K	Hold	700	–	–	﹤0.01%	221
2015 Q2	$4K	Hold	700	–	–	﹤0.01%	213
2015 Q1	$4K	Hold	700	–	–	﹤0.01%	255
2014 Q4	$2K	Hold	700	–	–	﹤0.01%	281
2014 Q3	$2K	Hold	700	–	–	﹤0.01%	186
2014 Q2	$2K	Hold	700	–	–	﹤0.01%	204
2014 Q1	$3K	Hold	700	–	–	﹤0.01%	221
2013 Q4	$2K	Buy	+700	New	+$1.42K	﹤0.01%	249

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Blume Capital Management's CORT Position: Q4 2021 in Review

Blume Capital Management sold out of Corcept Therapeutics (CORT) in Q4 2021, closing a stake of 700 shares — an estimated $14K sold.

Blume Capital Management first reported a position in CORT in Q4 2013 and held it in 32 quarters. The position peaked at $18K in Q4 2020. 208 funds tracked by Wall St. Rank hold CORT as of Q4 2021.

Blume Capital Management reported no remaining Corcept Therapeutics position as of Q4 2021 after selling out during the quarter.
Blume Capital Management sold 700 Corcept Therapeutics shares in Q4 2021, an estimated $14K.
Blume Capital Management first reported a position in Corcept Therapeutics in Q4 2013 and held it in 32 quarters.
Blume Capital Management's Corcept Therapeutics position peaked at $18K in Q4 2020.
208 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2021.

Based on Blume Capital Management's 13F filing for Q4 2021, filed 7 Feb 2022.